{"url_path":"/sec/xfor/8-k/2026-05-13/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K/A","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1501697/0001501697-26-000051-index.html","accession_number":"0001501697-26-000051","cik":"0001501697","ticker":"XFOR","issuer_name":"X4 Pharmaceuticals, Inc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1501697/0001501697-26-000051-index.html","primary_entity_key":"0001501697","primary_entity_name":"X4 Pharmaceuticals, Inc"},"word_count":163,"has_tables":true,"body_markdown":"Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\nAt the Annual Meeting, the Company’s stockholders approved the Company’s Second Amended and Restated 2017 Equity Incentive Plan (as so amended, the “Plan”) to increase the number of shares available for issuance under the Plan by 1,500,000 shares.\n\nFor additional information regarding the Plan, please refer to the heading “Material Features of the A&R 2017 Plan” contained in Proposal 3 of the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on March 20, 2026 (the “Proxy Statement”), which description is incorporated herein by reference.\n\nThe foregoing description and the summary contained in the Proxy Statement do not purport to be complete and are qualified in their entirety by reference to the full text of the Plan, a copy of which is filed as Exhibit 10.1 with this Current Report on Form 8-K and is incorporated herein by reference."}